Comparison of acute inflammatory and chronic structural asthma-like responses between C57BL/6 and BALB/c mice by Van Hove, C. L. et al.
 - 100 -    
  
Comparison of acute inflammatory and chronic structural asthma-like 
responses between C57BL/6 and BALB/c mice 
 
Chris L.Van Hove1*, Tania Maes1, Didier D. Cataldo2, Maud  Guéders2, Els Palmans3, Guy F. 
Joos1 and Kurt G. Tournoy1 
 
1Ghent University, Department of Respiratory Medicine, Ghent, Belgium 
2University of Liège and CHU of Liège, Department of Respiratory Diseases, GIGA-Research, Liège, Belgium 
3Hogeschool Gent, Ghent, Belgium 
 
International Archives of Allergy and Immunology, 2008 - (in press) 
 
 
In this manuscript, we investigated the effects of different durations of allergen exposure in 
sensitized mice belonging to two different strains. Inflammation, airway hyperresponsiveness 
and remodelling features were thoroughly characterized, while the influence of genetic 
background on these traits was considered. In addition, we established a basic model in which 
some of the asthma-like features (inflammation and airway hyperresponsiveness) could be 
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ABSTRACT  
 
Background: The interactions between airway responsiveness, structural remodelling, and 
inflammation in allergic asthma remain poorly understood. Prolonged challenge with inhaled 
allergen is necessary to replicate many of the features of airway wall remodelling in mice. In 
mice as well as in humans, genetic differences can have a profound influence on allergy, 
inflammation, airway responsiveness and structural changes. 
Methods:  The aim of this study was to provide a comparative analysis of allergen-induced 
airway changes in sensitized BALB/c versus C57BL/6 mice that were exposed to inhaled 
allergen for 2 (‘acute’), 6 or 9 weeks (‘chronic’). Inflammation, remodelling and 
responsiveness were analyzed. 
Results: Both strains developed a Th-2 driven airway inflammation with allergen-specific 
IgE, airway eosinophilia and goblet cell hyperplasia upon 2 weeks of allergen inhalation. This 
was accompanied by a significant increase in airway smooth muscle mass and 
hyperresponsiveness in BALB/c but not C57BL/6 mice. Contrarily, airway eosinophilia was 
more pronounced in the C57BL/6 strain.  
Chronic allergen exposure (6 or 9 weeks) resulted in an increase in airway smooth muscle 
mass as well as sub-epithelial collagen and fibronectin deposition in both strains. The 
emergence of these structural changes paralleled the disappearance of inflammation in both 
C57BL/6 and BALB/c mice and loss of hyperresponsiveness in the BALB/c strain. TGF-β1 
was accordingly elevated in both strains. 
Conclusion: Airway inflammation, remodelling and hyperresponsiveness are narrowly 
intertwined processes. Genetic background influences several aspects of the acute allergic 
phenotype. Chronic allergen exposure induces a marked airway remodelling that parallels a 
decreased inflammation, largely comparable between both strains.  
 
Key words: airway remodelling, asthma, mouse models, TGF-β, tolerance 
 
LIST OF  NON-STANDARD ABBREVIATIONS 
AHR = Airway Hyperresponsiveness; OVA = Ovalbumin; PBS = Phosphate-Buffered Saline; BALF = Broncho-
alveolar Lavage Fluid; i.p.= intraperitoneal; TGF-β= Transforming Growth Factor beta; HBSS= Hanks’ 
Balanced Salt Solution; PAS= Periodic Acid Schiff; IHC= Immunohistochemistry; DAB= 3, 3’-
diaminobenzidine; Penh = Enhanced Pause; ASM= Airway Smooth Muscle;SEM = Standard Error of the Mean; 
ANOVA = Analysis Of Variance; ECM = Extracellular Matrix 
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INTRODUCTION 
In addition to inflammation-related changes such as cellular infiltration and oedema, 
asthmatic airways display structural alterations referred to as “airway remodelling” [1;2]. 
Historically, animal models have proven useful for the elucidation of the immunological 
mechanisms of the Th-2 driven airway inflammation present in the asthmatic airway.  These 
models of allergic airway inflammation usually rely on short-term (1 day to 2 weeks) inhaled 
allergen after a systemic sensitization [3]. These models are not adequate to study the features 
of airway remodelling observed in patients with asthma, as longer periods of allergen 
exposure are required to mimic these changes [4;5]. The patho-physiology of airway 
remodelling remains largely unknown, but the structural alterations in the airway are thought 
to result from (inadequate) attempts of tissue repair in response to inflammation [6]. In 
addition, it is up to now unclear to what extent this process contributes to the deterioration of 
asthma symptoms [7] or represents the translation of a repair response that protects against 
further allergen-induced airway inflammation and bronchoconstriction [8]. The pattern of 
these structural changes differs between mouse strains [9], suggesting the genetic background 
might be important. Whether remodelling develops uniformly in all asthma patients is equally 
unclear [10].  
Remarkably, prolonged challenge with inhaled allergen in sensitized mice is often associated 
with disappearance of eosinophilic airway inflammation and the induction of a state of 
respiratory tolerance [11-14]. While the immunological mechanisms of this phenomenon are 
still poorly understood, tolerance appears to develop in most models using chronic allergen 
challenge [9;14].  
Although a wide variety of mouse asthma models exist [3;9;15;16], it remains puzzling how 
airway inflammation, remodelling and responsiveness relate to each other in these models. 
Thus, we here aimed to provide a thorough characterisation encompassing an assessment of 
inflammation and airway (hyper)responsiveness (AHR), as well as of the remodelling features 
in the two most commonly used mouse strains to study asthma, in casu C57BL/6 and BALB/c 
mice. We provide this comparative analysis in order to gain insight into the relationship 
between these asthma characteristics in both strains. We found that upon short-term 
challenge, both strains developed differential responses in inflammation, AHR and airway 
remodelling, particularly smooth muscle (ASM) proliferation. Upon prolonged exposure, both 
strains developed more similar structural airway alterations that paralleled a disappearance of 
eosinophilic inflammation and AHR. 
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MATERIALS AND METHODS 
 
Animals 
C57BL/6 and BALB/c mice (males, 6-8 weeks old) were purchased from Harlan (Zeist, the 
Netherlands). All experimental procedures were approved by the local ethical committee for 
animal experiments (Faculty of Medicine and Health Sciences, Ghent University).   
 
Allergen Exposure Protocols 
All groups of mice (6-12 mice/group) were sensitized with 10 µg intraperitoneal (i.p.)  OVA 
(Grade III; Sigma, St-Louis, MO) adsorbed to 1 mg Al(OH)3 on day 0 (d0) and d7. From d14 
onward, the mice were exposed to aerosolized (Ultraschallvernebler Sirius Nova, Heyer 
Medizintechnologie, Bad Ems, Germany) OVA (1% wt/v) or PBS 30 min/day, three times a 












Figure 1: Allergen exposure protocols. Exposure of sensitised C57BL/6 and BALB/c mice to OVA aerosols for 
2, 6 and 9 weeks (Protocols A, B and C respectively) 
 
Bronchoalveolar Lavage Fluid (BALF): cellular analysis  
Twenty-four hours after the last aerosol exposure, mice were sacrificed with an i.p. 
pentobarbital injection (60 mg/kg; Sanofi, Libourne, France). Briefly, BALF was taken by 
instillation of HBSS via a tracheal cannula. Three lavages with 0.3 ml HBSS followed by 
three lavages with 1 ml HBSS were performed. The recovered BALF of the first three 
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was then added to the rest of the lavage fluid, centrifuged, subjected to red blood cell lysis and 
resuspended for cell counts on cytospins (May-Grünwald/Giemsa).   
 
Histology 
After fixation of the left lung with 4% paraformaldehyde, slices from all left lobes were 
embedded in paraffin for histological analysis. Sections of 3 µm were stained with Congo Red 
to highlight eosinophils, Periodic-Acid Schiff (PAS) to highlight goblet cells and with Sirius 
Red for collagen staining. 
 
Immunohistochemistry (IHC) 
IHC for fibronectin was done in an analogous manner as previously described in the rat [17]. 
Briefly, lung sections of 3 µm were deparaffinized, rehydrated and the non-specific binding 
sites were blocked with 1% blocking reagent in PBS (Boehringer, Mannheim, Germany). 
Excess reagent was removed and the sections were incubated for 1h with a mouse anti-mouse 
fibronectin antibody (Dako A/S, Glostrup, Denmark; dilution factor 1/750). Afterwards, 
sections were rinsed and incubated with a biotinylated secondary antibody for 30 min. Next, 
the primary antibody-secondary antibody complex was detected by streptavidin-biotinylated 
horseradish peroxidase complex. The substrate for the peroxidase was 3, 3’-diaminobenzidine 
(DAB, Dako), resulting in a brown reaction product for fibronectin quantification.  IHC for α-
actin smooth muscle contractile elements in the airways (ASM) was performed in an 
analogous manner, using an anti-mouse α-actin SM antibody (Dako; dilution factor 1/100) 
and DAB substrate, equally resulting in a brown reaction product. 
 
Quantitative measurements in the airway wall  
Quantitative measurements were performed in the airways of each animal with a perimeter of 
basement membrane (Pbm) ranging from 800 to 2000 µm, provided a reasonable cross section 
was available (ratio of minimal to maximal internal diameter smaller than 1.8). Measurements 
were performed on the digital representation of the airways using a Zeiss (Oberkochen, 
Germany) KS400 Image analyser system as described earlier [17]. Morphometrical 
parameters were marked manually: the area defined by the basement membrane (Abm) and 
the area defined by the total adventitial perimeter (Ao). The total bronchial wall area (WAt) 
was calculated (WAt=Ao-Abm) and normalized to the square of the Pbm. For the 
quantification of collagen deposition, the area in the airway wall covered by the Sirius Red 
stain was determined by the software (WCt) and normalized to Pbm. To evaluate the sub-
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epithelial fibronectin deposition and the ASM content of the airways, the area covered by the 
DAB stain (WFt and WαA) was determined in an analogous manner and also normalized to 
Pbm. Goblet cells were quantified on PAS stained sections. Results were expressed as number 
of goblet cells per millimeter basement membrane. Peribronchial infiltration with eosinophils 
was evaluated in lung sections stained with Congo Red and the total number of eosinophils 
per mm² bronchial wall was determined. All measurements were performed on 5 airways per 
mouse.   
 
IgE and protein quantification (ELISA) 
OVA-IgE in serum was measured with ELISA using coated microtiter plates and biotinylated 
polyclonal rabbit anti-mouse IgE. TGF-β1 was determined the BALF using ELISA kits (R&D 
Systems, Abingdon, UK).  
 
Assessment of airway responsiveness (AHR) 
Twenty-four hours after the last aerosol exposure AHR to methacholine was assessed in 
spontaneously breathing animals using a whole body plethysmograph system (Buxco; Buxco 
Electronics Inc., Troy, NY). Before performing readings, the system was calibrated by rapid 
injection of 1 ml air. Pressure differences between the main chamber containing mice and a 
reference chamber were recorded using the software BioSystem XA (version 157; Buxco). 
This pressure signal is caused by flow changes in the main box during the respiratory cycle of 
the animal. The value of ‘enhanced pause’ (Penh) is used here to monitor airway function 
[18], since it shows strong correlation with the airway resistance [19]. Penh = [(Te-Tr)/Tr] x 
(PEP/PIP) where Te is expiratory time (s), Tr is relaxation time or time of the pressure decay 
to 36% of total box pressure during expiration, PEP is peak expiratory pressure (cm H2O), and 
PIP is peak inspiratory pressure (cm H2O). For each mouse, data of were recorded at baseline, 
and after exposure to PBS or increasing concentrations of nebulized methacholine (2 – 81 
mg/ml), to assess AHR. The solutions were nebulized through an inlet of the main chamber 
during 1 min. Readings were taken during 5 min after each nebulization. Between readings 
Penh value returned to baseline. Cumulative dose-response curves were constructed for the 
changes in Penh after increasing doses of methacholine. The changes in Penh are expressed as 
percentage increase of maximum Penh value following methacholine challenge compared to 
the average Penh value after PBS-exposure (calculated by Analyst 1.29; Buxco). 
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Statistical analysis 
Data were analysed with the statistical packet SPSS 15.0 (SPSS Inc.; Chicago, IL). Reported 
values are expressed as mean ± Standard Error of the Mean (SEM). Mean values of 
parameters (including quantitative measurements in the airway wall as well as inflammatory 
cells and mediators) except Penh values were compared between the groups through the 
Kruskall -Wallis test for multiple comparisons (nonparametric testing). When significant 
differences were observed, post-hoc comparisons between groups were made, using the 
Mann-Whitney U-test with Bonferroni corrections. P-values less than 0.05 were considered 
significant. The dose-response curves of Penh were compared using ANOVA. The 
concentration of methacholine causing a 250% increase in baseline Penh (PC250 Penh) was 
calculated by log-linear interpolation of the dose-response curve.  
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RESULTS 
 
1. Airway inflammation in the BALF and bronchial walls 
OVA exposure for 2 weeks (Protocol A; Figure 1) altered the composition of the BALF 
leukocytes in both strains (Figure 2) as compared to the PBS exposed mice. Both strains 
developed a significant influx of mononuclear cells and eosinophils. The percentage of 
eosinophils in BALF was 21.16 ± 4.41 % in C57BL/6 vs 12.66 ± 4.08 % in BALB/c mice 
(p<0.05 BALB/c vs. C57BL/6).Only C57BL/6 had a discrete but significant concomitant 
BALF neutrophilia and a significant increase in total BALF cellularity and macrophages. 
Moreover, both strains developed peribronchial and perivascular eosiniphilic inflammation 
upon short-term challenge (Figure 3 A/B). C57BL/6 mice, but not BALB/c mice also 
possessed some degree of interstitial inflammation (Figure 3 C/D). 
The numbers eosinophils counted around the airways on Congo Red stained sections were 
significantly higher in the C57BL/6 strain compared to the BALB/c strain (Table 1). 
Upon longer OVA exposure (6 or 9 weeks – Protocol B and C; Figure 1) the BALF cell 
composition in OVA-challenged mice of both strains returned to the composition discerned in 
mice exposed to PBS (Figure 2). At those time points, only a slightly elevated number of 
eosinophils remained present in the bronchial walls of both mouse strains (Table 1). 
 
 
TABLE I. Peribronchial eosinophils in epithelium 










* p<0.05: OVA versus PBS 
 ¶ p<0.05: 6 and 9 weeks versus 2 weeks 
# p<0.05: BALB/c versus C57BL/6 
Exposure time Treatment Eosinophils (x102 cells/mm² airway wall) 
  BALB/c  C57BL/6  
2 weeks PBS 1.49±0.17 1.05±0.17 
 OVA 5.06±0.30* # 6.61±0.46* 
6 weeks PBS 0.93±0.10 0.57±0.09¶ 
 OVA 1.51±0.13* ¶ 1.11±0.09* ¶ 
9 weeks PBS 0.79±0.11¶ 0.69±0.10 
 OVA 1.03±0.08* ¶ 0.79±0.08¶ 































Figure 2: BALF total cell count and differentiation in OVA sensitised C57BL/6 and BALB/c mice exposed to 
OVA or PBS aerosols for 2 weeks (A) and 9 weeks (B).  The BALF total cell counts after 6 weeks of OVA or 
PBS exposure are not included, as the results are similar to the 9 weeks experiment in both strains. 
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Figure 3: Airway histology (Congo Red stainings) of OVA- sensitized and -challenged BALB/c (A) and 
C57BL/6 (B) mice (2 weeks OVA exposure; magnification size = x 200). (C) and (D) show Congo Red stained 
pictures of the lung parenchyma of OVA- sensitized and – challenged (2 weeks) with interstitial inflammation in 
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2. Serum OVA-IgE 
Whereas the PBS challenged C57BL/6 mice had very low OVA-IgE levels at all time points, 
the BALB/c counterparts developed increasing IgE levels attributable uniquely to the i.p. 
sensitization (Table 2). In the OVA challenged mice of both strains, OVA-IgE increased 
already after 2 weeks as compared to the PBS challenged counterparts. Upon chronic 
exposure, both strains hold elevated IgE, however, the titres were markedly higher in the 
BALB/c mice as compared to the C57BL/6 mice (p<0.05 BALB/c vs. C57BL/6).  
 
 
TABLE II. OVA-specific IgE levels in the serum after sensitization and 
exposure of BALB/c and C57BL/6 mice 
 
* p<0.05: OVA versus PBS 
¶ p<0.05: 6 weeks and 9 weeks versus 2 weeks 
# p<0.05: BALB/c versus C57BL/6 
 
 
3. Epithelial Remodelling: Goblet Cells 
Exposure to OVA resulted, comparably in both strains, in a significant increase in goblet cells 
from 2 weeks onward (Figure 4A/5A). This increase persisted after 6 and 9 weeks (Figure 
4A). However, in both allergen-challenged C57BL/6 and BALB/c mice, the goblet cells did 




Exposure time Treatment OVA- specific IgE (U/ml) 
  BALB/c  C57BL/6  
2 weeks PBS 7.60±1.02 2.22±0.55 
 OVA 41.75±5.28* 33.50±7.19* 
6 weeks PBS 29.11±2.54 ¶ # 6.38±1.80 
 OVA 96.30±10.67* ¶ # 49.18±9.00* 
9 weeks PBS 23.00±1.90 ¶ # 3.43±1.14 
 OVA 102.20±10.63* ¶ # 21.83±4.01* 
 - 111 -    
4. Airway Smooth Muscle (ASM) 
The amount of airway smooth muscle did not change over time in the PBS-exposed mice, 
either in BALB/c or in C57BL/6 mice (Figure 4B and 5B). Exposure to OVA allergen for 2 
weeks resulted in a significant increase in ASM staining only in BALB/c mice. However, 
longer allergen exposure periods induced an increase in ASM in both strains.   
 
5. Morphometry and deposition of ECM proteins 
 
Morphometry 
The total wall area (WAt) or airway wall thickness of large-sized airways did not differ in both 
strains exposed to either 2, 6 or 9 weeks of PBS (Figure 6A). Exposure to OVA allergen for 2 
weeks resulted in a significant increase in WAt
 
only in the BALB/c mice when compared to 
sham-exposed mice. However, longer allergen exposures induced a significant and persistent 
increase in WAt in both strains. 
Fibronectin& Collagen  
Fibronectin and collagen deposition were similarly increased in both genotypes after 6 and 9 
weeks, respectively (Figure 5C and 6B and Figure 5D and 6C).  
 
6. Airway (hyper-) responsiveness (AHR) 
BALB/c but not C57BL/6 mice developed a significant leftward shift in the dose-response 
curve to inhaled methacholine after 2 weeks OVA exposure (ANOVA; p<0.005 versus PBS; 
Figure 7 A/D). After a longer exposure period (6 or 9 weeks), no difference in the dose-
response curve was observed for both strains (Figure 7 B-C/E-F). The C57BL/6 mice were 
less responsive to methacholine than BALB/c mice. At 2 weeks the concentration of 
methacholine that caused a 250% increase in Penh from baseline in allergen-exposed 
C57BL/6 was 17.40 ± 5.92 mg/ml methacholine versus 4.69 ± 1.81mg/ml methacholine in 
BALB/c mice (p<0.05 BALB/c vs. C57BL/6).  
 
7. BALF proteins 
TGF-β1 levels in BALF were persistently increased after 2 (Protocol A) or 9 (Protocol C) 
weeks allergen exposure in both strains compared to control, PBS- exposed, mice in both 
strains (Figure 8).  
 
 























Figure 4:  Measurement of indicators of airway remodelling with increasing duration of OVA challenge in 
C57BL/6 and BALB/c mice (solid black bars = OVA group, open bars = PBS group; n= 6-12 mice/group).  
(A) Goblet cells (PAS) (B) Airway Smooth Muscle layer (IHC) 
* p<0.05 OVA vs PBS 
 
Figure 5 (next page): Histology pictures of the airways of C57BL/6 mice challenged with OVA or PBS aerosols 
for 2 or 9 weeks (magnification pictures = x 100). An inset with higher magnitude is included. All stainings were 
performed in the BALB/c strain as well, leading to analogous results at these time points.  
(A) PAS staining to highlight goblet cells in C57BL/6 mice challenged with OVA or PBS for 2 weeks (B) IHC 
with DAB substrate to highlight the increase in ASM contractile elements (brown colour) in BALB/c mice 
challenged with OVA or PBS for 9 weeks (C) IHC with DAB substrate to highlight fibronectin deposition 
(brown colour) in C57BL/6 mice challenged with OVA or PBS for 9 weeks (D) Sirius Red staining to highlight 
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Figure 6:  Measurement of indicators of airway remodelling with increasing duration of OVA challenge in 
C57BL/6 and BALB/c mice (solid black bars = OVA group, open bars = PBS group; n= 6-12 mice/group).  
(A) Airway wall thickening (Congo Red) (B) Fibronectin deposition (IHC) (C) Collagen deposition (Sirius Red) 
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Figure 7: AHR to nebulized methacholine in sensitized BALB/c (A, B and C) and C57BL/6 mice (D, E and F) 
exposed to OVA (closed squares) during 2 weeks (A and D), 6 weeks (B and E) and 9 weeks (C and F). 
ANOVA OVA vs PBS at 2 weeks: p<0.005. 
 
 















































































































































































































































































































Figure 8: Levels of TGF-β1 in the BALF of C57BL/6 (B) and BALB/c (A) mice in sensitized to OVA and 
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DISCUSSION 
 
We here document that in the two most commonly used mouse strains to model asthma, 
C57BL/6 mice and BALB/c mice, genetic background and the duration of allergen exposure 
have a profound impact on different aspects of the resulting pathological phenotype. Although 
the acute response in both strains was predominated by eosinophilic airway inflammation, 
only the BALB/c strain developed a significant airway smooth muscle hyperplasia and AHR. 
In an attempt to mimic more closely the features of chronic asthma, the response to longer 
periods of allergen exposure was predominated by airway remodelling while inflammation 
and AHR decreased in both strains. Although other groups have earlier described strain 
differences in response to various durations of OVA aerosol exposure [9], the current study 
gives a more detailed insight into the relationship of inflammation, remodelling and 
responsiveness in the two most commonly used mouse strains. 
 
Inflammation, AHR and airway remodelling are thought to be interdependent processes. A 
large variety of mouse models focus on a limited number of characteristics of asthma to study 
the underlying pathogenesis [14;15]. To study inflammation, these models mainly rely on 
(hyper-) acute, short-term exposure protocols. The reason for this is that the use of short-term 
exposure protocols is practical but also avoids the establishment of respiratory tolerance that 
can develop after prolonged allergen exposure [11-14]. However, long-term exposure 
protocols are usually applied to study the main features of airway remodelling [4;5;14;16]. In 
these models, inflammation and lung function tests are often either absent or partially 
described [4;5;20]. We chose to provide here a comprehensive analysis encompassing not 
only the assessment of inflammation and responsiveness, but also a thorough characterisation 
of remodelling characteristics. 
 
Here, we found that inflammation and remodelling behave differently in both strains, 
especially in the acute models, based on short-term allergen exposure (Protocol A). Both 
strains developed eosinophilic inflammation, as evident from BALF analysis and 
quantification of peribronchial eosinophilia. However, airway eosinophilia was more 
pronounced in the C57BL/6 mice in the acute model. This is in line with one earlier study, 
that also found that C57BL/6 mice are more susceptible to the development of airway 
eosinophilia [21]. In contrast, Shinagawa et al. found a more pronounced eosinophilia in 
BALB/c mice after repeated (chronic) intranasal OVA instillation [9]. We presume the 
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method of antigen exposure is critical in this respect, as we administered OVA 1% by aerosol 
whereas Shinagawa et al. administered OVA 0.1% intranasally. Serum OVA-IgE levels were 
more elevated in the BALB/c mice than in C57BL/6 after prolonged OVA challenge 
(Protocols B and C) confirming earlier findings that showed that BALB/c mice are IgE – 
prone [22]. This is also underscored by the fact that BALB/c mice, but not C57BL/6, have 
measurable IgE titres already after sensitization only.   
 
In the BALB/c mice we observed a significant increase in airway smooth muscle mass (ASM) 
already after 2 weeks of OVA challenge (‘acute’ - Protocol A), in contrast to the C57BL/6 
strain, where longer durations of allergen exposure were required to obtain such an ASM 
increase. In addition, AHR was present in BALB/c mice at that time point. This histological 
observation now adds up to the earlier descriptions that inbred mouse strains exhibit 
significant genetic variability in the airway calibre and development of AHR after antigen 
sensitization and exposure [9;23]. Although the contraction of ASM is the ultimate translation 
of the asthma pathology into physiologic disturbance in patients, it remains an unresolved 
issue if a larger smooth muscle mass is really the cause of the AHR [24;25]. Some studies 
indicate a clear link between ASM and AHR in both animal models and humans, since both 
AHR and increased ASM can persist after resolution of the airway inflammation [26-28], and 
mathematical models predict that airways with increased ASM narrow to a much greater 
extent than airways with less ASM volume [29]. One could speculate that the lack of AHR 
after 2 weeks of OVA exposure in C57BL/6 mice could be related to the absence of ASM 
hyperplasia. However, other factors could be involved. Firstly, the C57BL/6 strain developed 
a certain degree of interstitial inflammation, which was earlier also reported by another group 
[30]. Secondly, the airway anatomy of both strains is different [31]. These factors could both 
be of potential relevance to explain why AHR was observed only in the BALB/c strain. 
 
Prolonged allergen challenge (Protocols B and C) results in increased fibronectin and 
collagen deposition in the airway wall in both strains which is concordant with findings 
described by other authors [20;26;32-35]. We here document that this structural remodelling 
occurs in parallel with a decrease of the inflammatory cells in the BALF compartment to 
baseline in both strains and loss of AHR in BALB/c mice. We and others previously 
described that prolonged OVA challenge in these mice results in the establishment of 
respiratory tolerance, as they are unresponsive to new sensitizations [12]. To date, the precise 
mechanisms of the development of respiratory tolerance in mice repeatedly challenged with 
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OVA aerosols have not been elucidated, and both regulatory T cell-dependent [36] and 
regulatory T cell-independent [37] mechanisms have been proposed. One factor that may be 
important in the down-regulation of allergic airway inflammation and AHR over time could 
ageing of the mice, because some studies found that the capability of T cells to differentiate 
into Th-2 cells was reduced in aging mice [38;39]. In contrast, one recent study found that 
older mice developed increased allergic inflammation, but less pronounced AHR [40]. 
Moreover, we earlier documented that mice aged over 20 weeks can easily develop Th-2 
mediated airway inflammation [12]. Thus, the precise effect of ageing on allergic airway 
disease remains a matter of debate [39-41]. 
 
The exact role of the eosinophils in remodelling, inflammation and AHR is speculative. It is 
possible that the eosinophils could contribute to the initiation of collagen synthesis by 
fibroblasts during the acute inflammatory phase [42]. In our opinion, the few remaining 
eosinophils in the bronchial wall upon prolonged allergen exposure represent a small but 
measurable fraction deemed to vanish shortly thereafter. In the BALB/c mice, the decrease of 
eosinophilic inflammation and increase of fibrosis in the airway wall occurs in parallel with 
the loss of AHR. It is thus tempting to speculate that the remodelling process could occur in 
an attempt to protect against allergen-induced AHR and inflammation. Collagen and 
fibronectin deposition could indeed increase airway wall stiffness and oppose against 
extended narrowing of the airway wall. Moreover, the sub-epithelial fibrosis could decrease 
the amount of allergen exposure by shielding off the immune system from the allergens 
(‘wash-away’ effect). 
 
TGF-β1 is a key molecule involved in the regulation of both inflammation and remodelling in 
both humans and mouse models [43-46], and therefore represents a potential therapeutic 
target of interest. Increases in TGF-β1 are a constant finding for both mouse strains used here, 
in the acute and in the chronic exposure models. It could therefore be speculated TGF-β1 is 
activated quite early as an endogenous “anti-asthma” molecule to control inflammation 
[45;46], to promote remodelling [43;44;47] and thus to inhibit AHR [48]. Previous studies 
using neutralising antibodies for TGF-β1 gave however conflicting results on its role. One 
study found that anti-TGF-β1 antibody treatment could antagonize matrix deposition, smooth 
muscle cell proliferation and mucus production without affecting the airway inflammation 
[47]. In contrast, in a recent report – based on an intranasal OVA administration- it was 
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shown that anti-TGF-β1 treatment did not inhibit remodelling, but rather induced an 
exacerbation of the allergen induced airway changes suggesting that this mediator is not per 
se responsible of airway remodelling [49]. These authors even warned against the use of 
therapeutic strategies aimed at interfering with TGF-β1.   
 
The current study has some limitations. Firstly, for measuring airway responsiveness, we used 
the whole body plethysmograph, a method that has been criticised. There is evidence that 
Penh and airway resistance do not correlate under certain conditions, although 
plethysmography remains a valuable tool for explorative analysis [19;50]. When Penh can be 
used as a surrogate for invasive measurements, it can decrease cost, time and number of 
animals required for experiments. Secondly, in this study we could not provide in-depth 
explorations into the precise mechanisms that regulate the relationship between airway 
inflammation, remodelling and responsiveness. Although the limitations of this study should 
be taken into account, the current data provide researchers with clues to choose an appropriate 
asthma model for the particular aspects of the disease they want to investigate. 
 
In conclusion, genetic background has an impact on the different aspects of the acute allergic 
phenotype. These differences are far less pronounced when studying chronic allergen 
exposure, albeit the latter models are characterized mainly by remodelling but not 
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